Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Dr. Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Chungna National University | South Korea

Author Profile 

Scopus

Google Scholar

BIOGRAPHY OF SANG YEON CHO 🌟

EARLY ACADEMIC PURSUITS 🎓

Sang Yeon Cho embarked on his academic journey at Chungnam National University, where he earned his Bachelor's degree in Biochemistry in 2012. He further pursued an M.S. in Medicine, obtaining his MD degree in 2021. Currently, he is completing his Ph.D. in New Drug Discovery and Development, expected to graduate in February 2025. His strong foundation in the sciences has equipped him with the skills necessary for innovative research in the medical field.

PROFESSIONAL ENDEAVORS 🏥

Currently, Dr. Cho serves as the Vice Director of the Metro Neurosurgery Clinic in Daejeon, South Korea, since October 2022. Prior to this role, he was the Vice Director of Hurisarang Hospital from March 2021 to September 2022. His leadership positions reflect his commitment to advancing medical practice and enhancing patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR CANCER BIOLOGY 🔬

As the Director of ChoLab since 2018, Dr. Cho has focused on cancer genomics and new drug discovery. His research has investigated the molecular mechanisms underlying cancer, emphasizing drug resistance and therapeutic targets. He has actively contributed to several labs, including the Neuroglia Lab and the Nano Primo Research Center, showcasing his multidisciplinary approach to tackling complex medical challenges.

IMPACT AND INFLUENCE 🌍

Dr. Cho's work has significantly influenced the field of medical genetics and cancer research. His publications in high-impact journals highlight the clinical significance of his findings, making substantial contributions to understanding cancer prognosis and treatment. Through his research, he aims to bridge the gap between laboratory discoveries and clinical applications, improving patient outcomes.

ACADEMIC CITATIONS 📚

His research output includes numerous peer-reviewed articles in respected journals such as BMC Medical Genomics, Scientific Reports, and BMC Cancer, where he explores topics like drug resistance, immunotherapy biomarkers, and cancer prognosis. His findings have garnered attention and citations within the academic community, underscoring the relevance and quality of his work.

LEGACY 🏆

Dr. Cho's dedication to advancing cancer research and patient care has already left a mark on the field. His innovative approach, exemplified by multiple patents related to AI in healthcare and cancer diagnostics, positions him as a forward-thinking researcher poised to shape future developments in medical science.

FUTURE CONTRIBUTIONS 🔮

Looking ahead, Dr. Cho aims to continue his research in cancer treatment and drug discovery, integrating cutting-edge technologies like artificial intelligence to enhance therapeutic strategies. With his expected Ph.D. completion in 2025, he is set to further expand his contributions to the field and inspire the next generation of medical researchers.

NOTABLE PUBLICATIONS 📑

"A method for the observation of the primo vascular system in the thoracic duct of a rat" 

  • Authors: Kim, S., Jung, S.J., Cho, S.Y., Soh, K.-S., Kim, S.
  • Journal: Evidence-based Complementary and Alternative Medicine
  • Year: 2013

"Protocol for the Observation of the Primo Vascular System in the Lymph Vessels of Rabbits" 

  • Authors: Jung, S.J., Cho, S.Y., Bae, K.-H., ... Song, Y.-K., Soh, K.-S.
  • Journal:  Journal of Acupuncture and Meridian Studies
  • Year: 2012

Sami Nassar | Cancer Genetics and Genomics | Best Researcher Award

Dr. Sami Nassar | Cancer Genetics and Genomics | Best Researcher Award

Medical University of South Carolina | United States

Author Profile

Orcid ID

🌟 SAMI I. NASSAR: A DEDICATED JOURNEY IN MEDICINE AND RESEARCH

EARLY ACADEMIC PURSUITS 🎓

Sami I. Nassar began his academic journey at Columbia University, where he majored in Neuroscience and Behavior, graduating Cum Laude in 2019 with an impressive GPA of 3.94/4.00. His academic excellence earned him a place in the Psi Chi International Honor Society in Psychology for his outstanding achievements. This strong foundation in neuroscience laid the groundwork for his future medical career. He is currently pursuing his MD at Wayne State University, School of Medicine, where he is on track to graduate in June 2024, having achieved a Step 2 Score of 258—a testament to his dedication to medical excellence.

PROFESSIONAL ENDEAVORS 👨‍⚕️

Throughout his career, Nassar has actively engaged in clinical and research positions across prestigious institutions. His experience as a Research Fellow at the Medical University of South Carolina since 2024 has enabled him to delve into otolaryngological topics, including vertiginous disorders and suicide risk in head and neck cancer patients. At the Henry Ford Health System and Karmanos Cancer Institute, he contributed to significant research on molecular biomarkers and substance use among cancer patients, helping to push the boundaries of cancer research and patient care. His earlier roles, including work at Generation Next Fertility and Columbia University, demonstrate his practical skills in clinical and laboratory settings, offering a holistic approach to patient care and research. These roles also gave him experience in collaborating with medical professionals and managing clinical trials, which have been integral to his development as a medical researcher.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS AND GENOMICS 🔬

Nassar’s research has focused heavily on otolaryngology, head and neck cancer, and HPV-related carcinomas. His work on identifying molecular biomarkers and risk factors in cancer patients, such as those for suicide and substance use, has been groundbreaking. His research not only seeks to understand the molecular foundations of cancer but also aims to improve the quality of life for cancer patients. His investigations into tinnitus and vertiginous disorders add further depth to his research portfolio, contributing to patient outcomes in the field of ear, nose, and throat (ENT) medicine.

IMPACT AND INFLUENCE 🏆

Nassar's research has been widely recognized within the medical community, as seen through numerous awards. His work has been presented at leading conferences, such as the American Head and Neck Society's 11th International Conference, where he won the 3rd place poster award in the Education/Care Delivery category. His earlier recognition by the American Journal of Gastroenterology in 2021 further highlights his ability to contribute to diverse fields of medicine. His influence extends to peer-reviewed academic journals, where his manuscripts and abstracts have garnered attention, solidifying his reputation as a promising researcher.

ACADEMIC CITES 📚

Nassar’s work has been cited in reputable journals, including Cancer Epidemiology, Biomarkers & Prevention, and the American Journal of Gastroenterology. His published work on topics like teduglutide therapy for Short Bowel Syndrome and cancer epidemiology reflects his ability to contribute to high-impact scientific literature. These citations, alongside his ongoing manuscripts on suicide and substance use in cancer patients, illustrate his influence on ongoing medical research.

LEGACY AND FUTURE CONTRIBUTIONS 🌍

As a young and promising researcher, Nassar is poised to make even more significant contributions to the field of medicine. His research on biomarkers and immunochemotherapy for cancer treatment, as well as his ongoing investigation into the psychological aspects of cancer care, will likely have a lasting impact on both academic research and clinical practice. His focus on improving patient quality of life through research on mental health and substance use demonstrates his commitment to a holistic approach to medicine, one that integrates both physical and mental health outcomes. His legacy will undoubtedly include shaping future practices in otolaryngology, head and neck oncology, and biomolecular cancer therapy. With his continued drive and dedication, Nassar’s future contributions to medical science promise to push boundaries and pave the way for innovative treatments and care models.

NOTABLE PUBLICATIONS 📑

"S3030 Safety and Efficacy of Teduglutide Therapy for Management of Short Bowel Syndrome After Intestinal Transplantation" 

  • Authors: Sami I. Nassar; Syed-Mohammed Jafri
  • Journal: American Journal of Gastroenterology
  • Year: 2021

"Abstract C067: Disparities in health literacy in patients with head and neck cancer: Considerations for understanding" 

  • Authors: Aleksandra Vidovich; Amy Williams; Samantha H. Tam; Mary K. Miller; Maria Olex; Sami Nassar; Alex Rodriguez; Eric Adjei Boakye
  • Journal: Cancer Epidemiology, Biomarkers & Prevention
  • Year: 2023

"The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine"

  • Authors: Sami I. Nassar; Amber Suk; Shaun A. Nguyen, MD; Dauren Adilbay; John Pang; Cherie-Ann Nathan
  • Journal: Cancer
  • Year: 2024

Gang liu | Cancer | Best Researcher Award

Prof Gang liu | Cancer | Best Researcher Award

Gansu Provincial Center for Disease Control and Prevention | China

Author Profile

Scopus

Gang Liu: Pioneer in Radiobiology and Preventive Medicine ⚛️

EARLY ACADEMIC PURSUITS 🎓

Gang Liu began his academic journey at Lanzhou University, where he pursued a PhD in preventive medicine. His graduation in 1997 marked the beginning of a career dedicated to understanding the impacts of radiation on health. His academic training in preventive medicine provided the foundation for his future contributions to radiobiology and public health, particularly in the context of disease control and prevention.

PROFESSIONAL ENDEAVORS 🏢

After obtaining his PhD, Gang Liu embarked on a distinguished career at the Gansu Provincial Center for Disease Control and Prevention. His professional focus has been on the intersection of radiobiology, immunology, and tumor screening. In 2019, his registration as a health physicist signaled a significant milestone. He became the technical lead for a groundbreaking study on low-dose dose-effect relationships, a critical area in radiation therapy and safety. His expertise in radiation protection and therapy has earned him a prominent position within the medical research community.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER🧬

Gang Liu's research primarily revolves around radiobiology and radiation protection in therapy. His technological advancements in biological dose estimation are considered cutting-edge within China and recognized internationally. One of his significant contributions was revising the 2011 IAEA Manual based on findings from his studies on radiological sensitivity and dose rates. This revision, coupled with his publications in the FASEB Journal, has made Liu a leading figure in radiation science. His work in chromosomal aberration analysis and developing noninvasive techniques for early-stage cancer screening underscores his innovative approach to medical research.

IMPACT AND INFLUENCE 🌍

Gang Liu's influence extends beyond national borders. His research on radiological sensitivity and dose rates, especially in the context of cancer screening and radiation therapy, has set new benchmarks in the field. The international recognition of his work, particularly his advancements in biological dose estimation and contributions to global radiation protection protocols, underscores his importance in radiobiology. His work is used by institutions worldwide to improve radiation safety standards and enhance cancer diagnostic techniques.

ACADEMIC CITATIONS 📚

His pioneering research has been published in prestigious journals such as the FASEB Journal, one of the top international platforms for scientific contributions. The citations of his work in radiological sensitivity, chromosomal aberration analysis, and cancer screening techniques reflect his deep impact on the scientific community, with his methods influencing both practical applications in healthcare and further research.

LEGACY AND FUTURE CONTRIBUTIONS 🔬

Gang Liu’s legacy will likely be defined by his leadership in advancing radiation protection technology and cancer screening techniques. As an innovator in radiological health, his influence will continue to grow through future contributions to radiation therapy safety, noninvasive cancer detection, and international health standards. His ongoing work in exploring new methods for biological dose estimation will further establish his standing as a key figure in the evolution of radiation medicine.

NOTABLE PUBLICATIONS 📑

"Study of Low-Dose Radiation Workers Ionizing Radiation Sensitivity Index and Radiation Dose-Effect Relationship" 

  • Authors: Liu, G., Zhang, R., Li, Y., Liu, Y.Y., Zhang, X.
  • Journal: Health Physics
  • Year: 2022

"Revision of cytogenetic dosimetry in the IAEA manual 2011 based on data about radio-sensitivity and dose-rate findings contributing" 

  • Authors:Liu, G.
  • Journal: FASEB Journal
  • Year: 2022

"Thyroid dose assessments due to inhalation of 131I for nuclear medicine workers"

  • Authors: Liu, G., Li, Y., Zhang, H., Niu, L.M., Zhang, R.
  • Journal: Frontiers in Public Health
  • Year: 2022

"Study of Indicators for Early and Rapid Diagnosis of Radiation Injury Is the Most Important in Patients With Cancer During Radiotherapy"

  • Authors: Liu, G., Niu, L.-M., Wang, L.-Q., Liu, Y.-Y., Zhang, R.
  • Journal: Dose-Response
  • Year: 2020

"Chromosomal aberration analysis: Novel noninvasive techniques for early-stage cancer screening"

  • Authors: Liu, G.
  • Journal: Clinica Chimica Acta
  • Year: 2024

Yong Chi Chua | Epigenetics | Best Researcher Award

Mr. Yong Chi Chua | Epigenetics | Best Researcher Award

University of Technology | Malaysia 

Author Profile

Scopus

🌟 Chua Yong Chi: AI Software Engineer Extraordinaire 🌟

🎓 Education

🎓 Master of Computer Science

University of Technology Malaysia
CGPA: 3.95 / 4.0, UTM National Postgraduate Fund (NPF) Scholarship
October 2021 - April 2023 | Skudai, Johor, Malaysia

🎓 Bachelor of Computer Science (Computer System)

University of Putra Malaysia
CGPA: 3.677 / 4.0, Second Upper Class Honour
October 2017 - September 2021 | Serdang, Selangor, Malaysia

💼 Professional Experience

🤖 AI Software Engineer

Redfin Technology
July 2023 - Present | Kuala Lumpur, Malaysia

  • Lead and coordinate an AI team to ensure timely completion of tasks.
  • Communicate effectively with project managers to gather requirements and align team efforts.
  • Utilize advanced knowledge in the RASA framework for AI chatbot development.
  • Implement NLP techniques including featurization, tokenization, data labeling, entity recognition, and intent classification.
  • Apply machine learning skills in feature engineering, classification, performance evaluation, and data modeling.
  • Conduct data analysis to extract and analyze conversation data, optimizing model performance.
  • Utilize TensorBoard to monitor model training.
  • Develop and deploy AI models using microservices architecture.
  • Implement web development using Vue.js, Spring Boot, and MySQL.
  • Create REST APIs to interact with databases for data validation and insertion.
  • Develop Docker containers for model training to handle OS dependency issues.
  • Use SQL queries for data insertion and extraction.
  • Debug code to identify and resolve errors efficiently.

💻 Java Developer Intern

Cyber Village
March 2021 – August 2021 | Kuala Lumpur, Malaysia

  • Collaborated with a team to develop a Fintech project using HTML, CSS, JavaScript (AngularJS), and Java (Spring Framework).
  • Tested web applications for bugs, documented processes, and fixed issues.
  • Assisted in creating a prototype for a new Fintech project by reusing existing code.

🔬 Projects

  1. Q-learning Model for Selection of Genetic Markers Associated with Acne
  • Developed a reinforcement learning agent using the Q-learning model to select genetic markers associated with acne.
  • Conducted data preprocessing and data mining for acne gene expression datasets using R programming.
  • Developed a Q-learning agent using Python (NumPy, pandas) and designed Markovian domains (state, action, rewards, Q-value) for the gene expression datasets.
  • Evaluated the performance of selected genes with logistic regression classification and analyzed their relationship with acne through PubMed text data mining.
  1. A Microservices Based Framework for IoT System in Smart Home Environment
  • Developed an IoT environment system on Raspberry OS and Docker, including temperature and humidity monitoring, light intensity monitoring, and light automation.
  • Created independent and loosely coupled features using different API IDs for each sensor.
  • Developed a messaging protocol between sensor and server using MQTT (Eclipse Mosquitto), backend function and API using JavaScript (Node-RED), database storage using InfluxDB, and data visualization using Grafana.

📚 Publications

AI-driven Q-learning for Personalized Acne Genetics: Innovative Approaches and Potential Genetic Markers
Published in the Egyptian Informatics Journal
Read more

💡 Skills

  • Programming Languages: Python, Java, R, JavaScript (AngularJS, Vue.js)
  • Frameworks & Tools: RASA, Spring Boot, Docker, TensorBoard, Git, GitLab, Visual Studio Code, Eclipse
  • Databases: MySQL, InfluxDB
  • Technologies: Microservices architecture, REST API, SQL
  • Data Science: NLP, Machine Learning, Data Analysis, Feature Engineering

🏅 Activities

Event President
UPM 6th Modern Dance Performance - F6und, March 2020

  • Coordinated over 100 active members and involved over 1000 audiences.

Club President
UPM Extreme Dancer Club, October 2018 – October 2019

  • Led and communicated with a 25-member organization.

🌐 Additional Information

  • Languages: English, Chinese, Malay
  • Interests: Gym, Dancing, Travelling, Badminton

📚 Notable Publication

AI-Driven Q-Learning for Personalized Acne Genetics: Innovative Approaches and Potential Genetic Markers

Authors: Chua, Y.C., Nies, H.W., Kamsani, I.I., Nies, Y.H., Mohamad, M.S.
Journal: Egyptian Informatics Journal
Volume: 26
Pages: 100484
Year: 2024